Induction of p21 by the Wilms' tumor suppressor gene WT1

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1429-1434

  Englert, Christoph ^a   Maheswaran, Shyamala ^a   Garvin, A Julian ^b   Kreidberg, Jordan ^c   Haber, Daniel A ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; ZINC FINGER PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KIDNEY DEVELOPMENT; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS REGULATION; RAT; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0030900178     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hastie, N. The genetics of Wilms' tumor: a case of disrupted development. Annu. Rev. Genet., 28: 523-558, 1994.
2. Buckler, A., Pelletier, J., Haber, D., Glaser, T., and Housman, D. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol. Cell. Biol., 11: 1707-1712, 1991.
3. Pritchard-Jones, K., Fleming, S., Davidson, D., Bickmore, W., Porteous, D., Gosden, C., Bard, J., Buckler, A., Pelletier, J., Housman, D., van Heyningen, V., and Hastie, N. The candidate Wilms' tumour gene is involved in genitourinary development. Nature (Lond.), 346: 194-197, 1990.
4. Mundlos, S., Pelletier, J., Darveau, A., Bachmann, M., Winterpacht, A., and Zabel, B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues Development (Camb.), 119: 1329-1341, 1993.
5. Kreidberg, J., Sariola, H., Loring, J., Maeda, M., Pelletier, J., Housman, D., and Jaenisch, R. WT1 is required for early kidney development. Cell, 74: 679-691, 1993.
6. Pelletier, J., Bruening, W., Kashtan, C., Mauer, S., Manivel, J., Striegel, J., Houghton, D., Junien, C., Habib, R., Fouser, L., Fine, R., Silverman, B., Haber, D., and Housman, D. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash Syndrome. Cell, 67: 437-447, 1991.
7. Haber, D., Park, S., Maheswaran, S., Englert, C., Re, G., Hazen-Martin, D., Sens, D., and Garvin, A. WT1-mediated growth suppression of Wilms' tumor cells expressing a WT1 splicing variant. Science (Washington DC), 262: 2057-2059, 1993.
8. Rauscher, F. J., III. The Wilms' tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 7: 896-903, 1993.
9. Haber, D., Sohn, R., Buckler, A., Pelletier, J., Call, K., and Housman, D. Alternative splicing and genomic structure of the Wilms' tumor gene WT1 Proc. Natl. Acad. Sci. USA, 88: 9618-9622, 1991.
10. Larsson, S., Charlieu, J., Miyagawa, K., Engelkamp, D., Rassoutzadegan, M., Ross, A., Cuzin, F., van Heyningen, V., and Hastie, N. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing Cell, 81: 391-401, 1995.
11. Englert, C., Vidal, M., Maheswaran, S., Ge, Y., Ezzell, R., Isselbacher, K., and Haber, D. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc. Natl. Acad. Sci. USA, 92: 11960-11964, 1995.
12. Englert, C., Hou, X., Maheswaran, S., Bennett, P., Ngwu, C., Re, G., Garvin, A., Rosner, M., and Haber, D. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J., 14: 4662-4675, 1995.
13. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G., and Haber, D. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev., 9: 2143-2156, 1995.
14. 1 phase arrest induced by Wilms' tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc. Natl. Acad. Sci. USA, 92: 4517-4521, 1995.
15. El-Deiry, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, R., Lin, D., Mercer, E., Kinzler, K., and Vogelstein, B. WAF-1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
16. Gu, Y., Turck, C., and Morgan, D. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
17. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
18. Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
19. Zhu, L., Harlow, E., and Dynlacht, B. D. p107 uses a p21 CIP-related domain to bind cyclin/cdk2 and regulate interactions with E1F. Genes Dev., 9: 1740-1752, 1995.
20. Enders, G. H., Koh, J., Missero, C., Rustgi, A., and Harlow, E. H. p16 inhibition of transformed and primary squamous epithelial cells. Oncogene, 12: 1239-1245, 1996.
21. WAF1/CIP1 expression in normal and neoplaslic tissues. Cancer Res., 55: 2910-2919, 1995.
22. Van den Heuvel, S., and Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control Science (Washington DC), 262: 2050-2054, 1993.
23. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow. E. Inhibition of cell proliferation by p 107, a relative of the retinoblastoma protein. Genes Dev., 7: 1111-1125, 1993.
24. Masuda, H., Miller, C., Koeffler, H., Battifora, H., and Cline, M. Rearrangements of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA, 84: 7716-7719, 1987.
25. Haber, D., Buckler, A., Glaser, T., Call, K., Pelletier, J., Sohn, R., Douglass, E., and Housman, D. An internal deletion within an 11 p13 zinc finger gene contributes to the development of Wilms' tumor. Cell, 61: 1257-1269, 1990.
26. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
27. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671-680, 1990.
28. MacLeod, K., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
29. Wang, Z-Y., Qiu, Q-Q., and Deuel, T. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J. Biol. Chem., 268: 9172-9175, 1993.
30. Duan, D. R. Pause, A., Burgess, W. H., Aso, T., Chen, DYT., Gatten, KP., Conaway, R. C., Conaway, J. W., Linehan, M., and Klausner, R. D. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (Washington DC), 269: 1402-1406, 1995.
31. Kibel, A., Iliopoulos, O., DeCaprio, J. A., and Kaelin, W. G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (Washington DC), 269: 1444-1446, 1995.
32. Halevy, O., Novitch, B., Spicer, D., Skapek, S., Rhee, J., Hannon, G., Beach, D., and Lassar, A. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
33. Jiang, H., Lin, J., Su, Z-Z., Collart, F., Huberman, E., and Fisher, P. Induction of differentiation in human promyelocytic HL60 leukemia cells activates p21, WAF1/Cip1, expression in the absence ofp53. Oncogene, 9: 3397-3406, 1994.
34. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10: 142-153, 1996.
35. Cip1 in muscle and other terminal differentiating cells. Science (Washington DC), 267: 1024-1027.
36. Skapek, S., Rhee, J., Spicer, D., and Lassar, A. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science (Washington DC), 267: 1022-1024, 1995.
37. Steinman, R., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D., and El-Housseini, M. Induction of p21 (WAF1-CIP1) during differentiation. Oncogene, 9: 3389-3396, 1994.
38. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
39. Wang, J., and Walsh, K. Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.